Medindia LOGIN REGISTER
Medindia
Advertisement

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR

Tuesday, December 4, 2018 General News
Advertisement
NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).  
Advertisement

The investigation concerns whether United Therapeutics and certain of its officers and/or directors have breached fiduciary duties owed to the company and its investors.
Advertisement

If you are a shareholder of United Therapeutics and are interested in obtaining additional information regarding this investigation,  you are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:Robert S. WilloughbyPomerantz [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-united-therapeutics-corporation--uthr-300759417.html

SOURCE Pomerantz LLP

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close